ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Session » Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Therapeutic Strategies, Biomarkers and Predictors of Outcomes in Rheumatoid Arthritis

Meeting: 2014 ACR/ARHP Annual Meeting

Abstract Number: 2467
Effectiveness and Safety of Tocilizumab in Biologics Naïve RA Patients – Interim Analysis of PMS for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-Naïve RA Patients Study
Abstract Number: 2468
Stringent Criteria for Low Disease Activity and Remission after 12 Months of Treatment, and after Treatment Withdrawal, with Abatacept Monotherapy, Abatacept with Methotrexate or Methotrexate Alone in Early Rheumatoid Arthritis
Abstract Number: 2469
The Efficacy and Safety of Tocilizumab Subcutaneous Q2W and Following Escalation from Q2W to QW Therapy in Combination with Traditional Dmards in Patients with Moderate to Severe Rheumatoid Arthritis at 96 Weeks
Abstract Number: 2470
Treatment Strategy for Maximizating the Effect of Adalimumab in Japanese Patients with Rheumatoid Arthritis : Retrospective Analyses of Data Collected from the Patient Treated with Adalimumab in Routine Clinical Practice in Hamamatsu Area
Abstract Number: 2471
Effect of Teriparatide in Patients with Osteoporosis and Rheumatoid Arthritis
Abstract Number: 2472
The First, Multicenter, Double-Blind, Randomized, Parallel-Group Study of Certolizumab Pegol in Early Rheumatoid Arthritis Demonstrates Inhibition of Joint Damage Progression
Abstract Number: 2473
Post-Marketing Surveillance of Efficacy and Safety of Tacrolimus Add-on Therapy in Japanese Rheumatoid Arthritis Patients Who Failed to Show an Adequate Response to Biological Dmards : Interim Analysis
Abstract Number: 2474
Efficacy and Tolerability of Subcutaneous Methotrexate for Inflammatory Arthritis: A Retrospective Observational Cohort Study
Abstract Number: 2475
Multiple Approaches for Implementation of Long-Term Efficacy: Interpretation of Certolizumab Pegol Data in Rheumatoid Arthritis Case Study
Abstract Number: 2477
Integrating Treatment Goals of Physicians, Patients, and Payers during Treatment with Golimumab in Patients with Rheumatoid Arthritis
Abstract Number: 2478
Analysis of the Clinical Sustained Response after Retreatment with a Lower Dose of Rituximab in Patients with Chronic Inflammatory Arthropathies
Abstract Number: 2479
Utility of Adjustment of Administration Interval in Tocilizumab in Rheumatoid Arthritis
Abstract Number: 2480
Is there a Difference in the  Effectiveness in the Treatment of Rheumatoid Arthritis with Rituximab when Using a Dose of 1 or 2 Grams per Cycle? a Systematic Review
Abstract Number: 2481
Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with DMARDs in Rheumatoid Arthritis Patients in a Real Life Setting?: An Interim Analysis of Safety and Efficacy at 6 Months
Abstract Number: 2482
Use of Biologic Therapy As Monotherapy in Patients with Rheumatoid Arthritis
Abstract Number: 2483
Treatment Adjustment Strategy after Achieving Remission or Low Disease Activity in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis
Abstract Number: 2484
Adding an Initial Six-Month Course of Infliximab to an Active Combination Treatment Is Cost Saving in Working-Aged Early Rheumatoid Arthritis Patients
Abstract Number: 2485
Predictors of Drug-Free Remission Following Treatment with Abatacept (in Combination with Methotrexate or as Monotherapy) in Early Rheumatoid Arthritis
Abstract Number: 2486
Patient-Reported Outcomes Following 12 Months of Therapy with Abatacept (Plus Methotrexate or as Monotherapy) or Methotrexate and up to 6 Months after Treatment Withdrawal in Patients with Early Rheumatoid Arthritis
Abstract Number: 2487
Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis
Abstract Number: 2488
Relationship Between Different Clinical Measurements and Patient-Reported Outcomes
Abstract Number: 2489
Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis
Abstract Number: 2490
Assessment of Structural Benefits of SC Abatacept Using MRI in Patients with RA Who Have Failed 1 or 2 TNFs and Correlated with Clinical Outcomes As Measured By DAS28(ESR)
Abstract Number: 2491
Prognostic Factors for IV Abatacept Retention in Patients Who Have Received at Least One Prior Biologic Agent: 2-Year Results from a Prospective, International, Real-World Study
Abstract Number: 2492
Does Body Mass Index Impact Long-Term Retention with Abatacept in Patients with RA Who Have Received at Least One Prior Biologic Agent? 2-Year Results from a Real-World, International, Prospective Study
Abstract Number: 2493
Prediction of Remission and Low Disease Activity in DMARD-Refractory Patients with RA Treated with Golimumab
Abstract Number: 2494
Persistence on Single Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis Is Extremely Rare
Abstract Number: 2495
Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis:   5-Year Data from 3 Phase III Clinical Trials
Abstract Number: 2496
Predictors of ACR/EULAR Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Abstract Number: 2497
Correlation Between Time to  Switch  and Clinical Response Amplitude to  Rituximab in Second  Line  Treatment  in Rheumatoid Arthritis  Patients with Treatment Failure to Tumor Necrosis Factor Inhibitors: 3-Year Data from Repeat Observational Study
Abstract Number: 2498
Characteristics of Responding Versus Non-Responding Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate
Abstract Number: 2499
Early Response Indicator early Predicts Clinical Response to Certolizumab in Rheumatoid Arthritis Patients
Abstract Number: 2500
Genetic Variation in the TLR5 Locus Is Associated with Anti-TNF Response Among Rheumatoid Arthritis Patients
Abstract Number: 2501
Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis
Abstract Number: 2502
Ten Year Follow-up Results of Four Dynamic Treat to Target Strategies in Patients with ACPA Negative Rheumatoid Arthritis
Abstract Number: 2503
Early Response to Full-Dose Etanercept-Plus-Methotrexate Induction Therapy Predicts Sustained Remission with Reduced-Dose Combination Therapy in Early Rheumatoid Arthritis Patients
Abstract Number: 2504
Impact of Concomitant Methotrexate on the Enhanced Clinical Efficacy of Abatacept after 24 Weeks in Rheumatoid Arthritis Patients
Abstract Number: 2505
Long-Term Treatment with Tocilizumab (TCZ) Strongly Suppresses Joint Destruction in Biologic-naïve Patients with Rheumatoid Arthritis (RA) Regardless of Inflammation Status
Abstract Number: 2506
Decrease in the Number of Peripheral Leukocytes and Neutrophils and Increase of the Percentage of Eosinophils at 4 Week Predict the DAS28-ESR Remission at 24 Weeks after Administration of Tocilizumab
Abstract Number: 2507
Is There an Autoinflammatory Component in Rheumatoid Arthritis Associated with Better Response to Anakinra (Kineret®)?
Abstract Number: 2508
Tocilizumab Serum Trough Levels and Its Relationship with Disease Activity and Drug Dosage in Rheumatoid Arthritis Patients
Abstract Number: 2509
ADAM-10 As a Tocilizumab Treatment Predictive Factor in Rheumatoid Arthritis
Abstract Number: 2510
Good Response to Methotrexate (MTX) and/or MTX Plus Adallimumab (ADA): 3 Yrs Study Results in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 2511
Predictors of Discontinuation of Biologic DMARD Therapy Due to Remission in Patients with Rheumatoid Arthritis in a National Registry
Abstract Number: 2512
Golimumab Therapy Retention Rates in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthritis: Data from the Italian Lorhen Registry
Abstract Number: 2513
The Monitoring of Infliximab Levels at Early Stages Can Predict the Development of Anti-Infliximab Antibodies in a Cohort of Rheumatoid Arthritis Patients Treated with Infliximab
Abstract Number: 2514
Biological Treatment for Rheumatoid Arthritis (RA): A Fifteen Years Multicentric Overview
Abstract Number: 2515
Serum Survivin in Early Rheumatoid Arthritis
Abstract Number: 2516
Reasons and Risk Factor for Discontinuation of Biologic Agents in Rheumatoid Arthritis Patients
Abstract Number: 2517
Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders
Abstract Number: 2518
What Is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors?
Abstract Number: 2519
Are Patients with Rheumatoid Arthritis Initiating a TNF Biologic Comparable to Patients Initiating a Non TNF?
Abstract Number: 2520
Patient, Genetic and Disease Factors Influence the Response to the Disease Modifying Anti-Rheumatic Drug Leflunomide
Abstract Number: 2521
Analysis on Predictors for Long-Term Clinical Efficacies of Golimumab in Patients with Rheumatoid Arthritis
Abstract Number: 2522
Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations
Abstract Number: 2523
Are Biologic Agents Effective on the Treatment of Secondary Amyloidosis: A Multicenter Report on Turkish Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Abstract Number: 2524
Smoking and Response to Rituximab in Anti-CCP Positive and Negative Rheumatoid Arthritis – Results from an International European Collaboration
Abstract Number: 2525
Infliximab Versus Conventional Combination Treatment and Work Loss in Early RA over 7 Years: A Randomized Trial
Abstract Number: 2526
Efficacy of Biological Therapies in Rheumatoid Arthritis: Graphical Modeling of DAS28 Components’ Evolution over Time
Abstract Number: 2527
The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts
Abstract Number: 2528
Efficacy Meta-Analysis of Randomized Controlled Trials (RCTs) of Biologics in Methotrexate-Naive Patients with Early Rheumatoid Arthritis
Abstract Number: 2529
Efficacy of Infliximab, Adalimumab, and Tocilizumab Can be Improved Under the Baseline ADAMTS5 Selection
Abstract Number: 2530
PRE.MARK-TNF Test Based on Iga-Specific Autoantigens Predicts Therapy Response in Rheumatoid Arthritis Patients Treated with TNFα Inhibitors

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies